Amsterdam, 18 - 19 March 2020

Schedule

Create your personal agenda –check the favourite icon

Mar 1808:55
Conference pass

Chair’s opening remarks

Keynotes
Ryan Saadi, Vice President, Global Market Access, CSL Behring
Mar 1809:00
Conference pass

Global implications of pricing & access developments in the US

Keynotes
Wendy Jory, Head Of Global Pricing Centre Of Excellence, GlaxoSmithKline
Mar 1809:20
Conference pass

Orphan Drugs, Gene Therapies, Post-Marketing-Data: Latest developments in German legal framework for drug assessment and reimbursement

Keynotes
Thomas Mueller, Head Of Directorate General 1 "Drugs, Medical Devices, Biotechnology", Federal Ministry of Health Germany
Mar 1812:00
Conference pass

Roundtable 10: Accelerating access to treatments for rare diseases

Keynotes
Mar 1812:00
Conference pass

Roundtable 11: Topic TBC

Keynotes
Mar 1812:00
Conference pass

Roundtable 6: A tale of two diseases: how orphan drugs can navigate NICE

Keynotes
Mar 1812:00
Conference pass

Roundtable 7: Achieving positive reimbursement negotiations

Keynotes
Mar 1812:00
Conference pass

Roundtable 8: The development of a patient advocate – How to find experienced and qualified patient advocates- The Continual Professional Development approach

Keynotes
Mar 1812:00
Conference pass

Roundtable 9: Using Health Economic Studies to Support Access and Value

Keynotes
Mar 1812:00
Conference pass

Roundtables 1: Efficacy to Effectiveness - E2E – translating the promise of clinical trials to the real world

Keynotes
Mar 1812:00
Conference pass

Roundtables 2: How do you include the patient perspective in a outcomes-based contract?

Keynotes
Mar 1812:00
Conference pass

Roundtables 3: Capability building for RWE

Keynotes
Mar 1812:00
Conference pass

Roundtables 4: Payer insights and engagement for BeneLux

Keynotes
Mar 1812:00
Conference pass

Roundtables 5: Payer insights and engagement for Italy

Keynotes
Mar 1814:10
Conference pass

Chair’s remarks

Track 1
Chris Pashos, Vice President Of Global Evidence Strategy, AbbVie
Mar 1814:10
Conference pass

Chair’s remarks

Track 2
Gustavo Saraiva Dos Anjos, Head Of Market Access, Respiratory Pipeline, GlaxoSmithKline
Mar 1814:10
Conference pass

Chair’s remark

Track 4
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Mar 1814:10
Conference pass

Chair’s remarks

Track 6
Navin Joshi, Global Head of Pricing, Classic & Established Products. Global Pharma, Head of Pricing & Access Capabilities, Emerging Markets, GlaxoSmithKline
Mar 1814:15
Conference pass

Can Pharma save $1 billion through the strategic use of RWE?

Track 1
Melvin Olson, Global Head Rwd Strategy And Innovation, Novartis Pharma
Mar 1814:15
Conference pass

New and improved outcomes-based contracting: new implementation

Track 2
Jolanda Koenders, Head Of Pricing And Market Access Pharma, Novartis
Mar 1814:15
Conference pass

Registries and reimbursement for orphan drugs in Germany

Track 3
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Mar 1814:15
Conference pass

From Digital To Big Data Analytics & AI In Real World Data

Track 4
Igor Rudychev, Head of US Digital, Data, and Innovations, AstraZeneca
Mar 1814:15
Conference pass

Innovation in the HTA process: facilitating UK market access

Track 5
Stephen Hall, Knowledge Exchange Associate, NIHR Innovation Observatory, Newcastle University
Mar 1814:15
Conference pass

HTA insights for South Korea

Track 6
Jeonghoon Ahn, Director, National Evidence-based Healthcare Collaborating Agency
Mar 1814:15
Conference pass

Latest developments in value frameworks

Track 7
Gwilym Thompson, Director Worldwide Heor, BMS
Mar 1814:55
Conference pass

Value-based Contracting Status and Outlook

Track 2
Birgit Holz, Global Head Of Contracting Innovation, Sanofi
Mar 1814:55
Conference pass

The continuing changing landscape in creating value beyond price for rare disease products in the US

Track 3
Diann Potestio, Vice President Market Access, Ascendis Pharma
Mar 1814:55
Conference pass

Diabetes care in the world of digital health: What does the evidence say?

Track 4
Mar 1815:15
Conference pass

Chair’s remarks

Track 2
Andrew Richards, Head Of Global Market Access And Pricing, Ferring
Mar 1815:15
Conference pass

Chair’s remarks

Track 5
Kevin Rieger, Head Of Eu Affairs, BPI
Mar 1815:15
Conference pass

Chair’s remarks

Track 7
Gavin Lewis, Vice President Of Value, Access And Policy, Amgen
Mar 1815:20
Conference pass

Living with and Beyond Cancer: The Missing Evidence

Track 1
Richard Stephens, Patient Advocate, National Cancer Research Institute (NCRI)
Mar 1815:20
Conference pass

Market access for gene therapies in Germany

Track 2
Axel Boehnke, Director Market Access EU North, PTC Therapeutics
Mar 1815:20
Conference pass

Developing advanced therapies for rare diseases: is this sustainable?

Track 3
Diego Ardigo, R&D Rare Diseases Unit Head, Chiesi Farmaceutici SpA
Mar 1815:20
Conference pass

Big data & AI in pricing and access to medicines

Track 4
Francis Crawley, Executive Director, Strategic Initiative For Developing Capacity In Ethical Review (Sidcer), Good Clinical Practice Alliance (GCPA)
Mar 1815:20
Conference pass

HTA for Switzerland and stakeholder engagement

Track 5
Mar 1815:20
Conference pass

How we deliver value with the patient in mind

Track 7
Peter Mulley, Director Global Market Access, ViiV Healthcare
Mar 1816:00
Conference pass

User cases of federated data in oncology

Track 1
Enkeleida Nikai, Head Of Real World Evidence, Senior Director At Janssen Europe, Middle East And Africa (Emea), Janssen Pharmaceutical
Mar 1816:00
Conference pass

Access, Pricing and Value in the world of oncology and combination therapies

Track 2
Patrick Mollon, HEOR Consultant, GMAP, Ipsen Pharma
Mar 1816:00
Conference pass

The link between HTA and decision-making in resource allocation

Track 6
Andres Pichon Riviere, Executive Director And Director Of Health Technology Assessment And Economic Evaluations, I.E.C.S.
Mar 1816:00
Conference pass

How do traditional drugs deliver value in the world of gene therapies

Track 7
Juan Roman, Head of Market Access & Pricing, Acceleron Pharmaceuticals, Inc.
Mar 1816:50
Conference pass

Chair’s remarks

Track 1
Anjan Chatterjee, Global Head Of Real World Evidence, Boehringer Ingelheim Pharma GmbH & Co. KG
Mar 1816:50
Conference pass

Chair’s remarks

Track 2
Cristina Martin-Rinconada, Head Of Value And Access For International Partners Markets (Mena And Ceer Regions), Biogen
Mar 1816:50
Conference pass

Chair’s remarks

Track 3
Mark Duman, Nw Service Champion, Diabetes U.K.
Mar 1816:50
Conference pass

Chair’s remarks

Track 6
Martin Price, Vice President Of Health Economics, Market Access And Reimbursement, Johnson & Johnson
Mar 1816:50
Conference pass

Chair’s remarks

Track 7
Gundula Schneidewind, Head Ethics And Compliance, Europe And Canada, Takeda
Mar 1816:55
Conference pass

Evidence requirements for HTAs across Europe

Track 1
Giovanni Tafuri, EUnetHTA, Senior Scientific Officer, National Health Care Institute (ZIN), the Netherlands
Mar 1816:55
Conference pass

The Swedish market: Supporting regional payers in managed introduction and prioritisation of new drug therapies

Track 2
Mar 1816:55
Conference pass

The patient’s journey for neurological diseases

Track 3
Lara Pippo, Head Of Market Access, CSL Behring
Mar 1816:55
Conference pass

Digital Medicines: Where are we now and what next

Track 4
Oliver Gassner, Head Digital Health Intelligence | Emea, Bayer
Mar 1816:55
Conference pass

Should a large payer like AXA transform its role from prevention and care coordination to healthcare delivery

Track 5
Charles De Cidrac, Director Of Health Insurance, AXA
Mar 1816:55
Conference pass

Market access and pricing conditions across the Middle East and Africa

Track 6
Ayman Semaan, Head Of Market Access, Algorithm
Mar 1816:55
Conference pass

Chair’s remarksWhat is the government’s role in US pricing decisions?

Track 7
Robert Popovian, Vice President Of Government Relations, Pfizer
Mar 1817:15
Conference pass

Patient engagement in preparation for HTA submissions and acceptance of data

Track 1
Stefan Holmstrom, Head, HTA Strategy and PRO excellence, Astellas Pharma
Mar 1817:35
Conference pass

Looking at the evidence after launch: addressing access hurdles across different markets

Track 1
Rasmus Jensen, Global Head Of Market Access, Camurus
Mar 1817:35
Conference pass

Market access developments for Russia

Track 2
Daria Tolkacheva, Head Of Health Economics, JSC BIOCAD
Valentin Dodonov, Deputy General Head Of Market Access, BIOCAD
Mar 1817:35
Conference pass

The Hercules Project: Patient-led Access in Rare Diseases

Track 3
Josie Godfrey, Director, JG Zebra Consulting
Mar 1817:35
Conference pass

Developing a data strategy to meet business needs

Track 4
Waldemar Ockert, Director, Rwi Business Market Analytics, Astellas Pharma
Mar 1817:35
Conference pass

Payer engagement in Italy and across Europe

Track 5
Andrea Mantovani, Former Head of Value, Access & Policy for Biopharma Companies, Independent
Mar 1817:35
Conference pass

The Sanofi Espoir Foundation- improving access in Africa

Track 6
Valerie Faillat, Head Of Sanofi Espoir Foundation, SANOFI
Mar 1817:35
Conference pass

How the political climate is changing the necessity for fairer pricing

Track 7
Ad Schuurman, Senior Advisor International Affairs, National Health Care Institute (ZIN), the Netherlands

Create your personal agenda –check the favourite icon

Mar 1908:55
Conference pass

Chair’s opening remarks

Keynotes
Sarah Pitluck, Head, Global Pricing And Reimbursement, Spark Therapeutics
Mar 1909:00
Conference pass

Market Access considerations from NICE

Keynotes
Carla Deakin, Programme Director - Commercial And Managed Access, NICE
Mar 1909:40
Conference pass

Achieving greater stakeholder engagement and innovation to improve outcomes

Keynotes
  • What are the key initiatives in Europe and across the world aimed at improving cooperation?
  • How is innovation in access, pricing or evidence helping to improve outcomes?
  • How can we work better together with key stakeholders to improve health care efficiency?
Tamir Singer, Head Of Commercial Development, Specialised Commissioning, NHS England
Ulrike Jacobi, Head Of External Affairs And Market Access, Amgen
Gustavo Saraiva Dos Anjos, Head Of Market Access, Respiratory Pipeline, GlaxoSmithKline
Mar 1911:00
Conference pass

Roundtable 5: Exploring the evolution of the value framework to assess drugs in Italy

Keynotes
Mar 1911:00
Conference pass

Roundtable 6: Advanced technologies and registry design

Keynotes
Mar 1911:00
Conference pass

Roundtable 7: Exploring Biosimilars in the USA and latest developments

Keynotes
Mar 1911:00
Conference pass

Roundtables 1: Innovation in Contracting

Keynotes
Mar 1911:00
Conference pass

Roundtables 2: Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve outcomes

Keynotes
Mar 1911:00
Conference pass

Roundtables 3: Exploring innovative payment and evidence development models for rare diseases

Keynotes
Mar 1911:00
Conference pass

Roundtables 4: How to improve the environment for value-added medicines in Europe

Keynotes
Mar 1912:00
Conference pass
Mar 1912:00
Conference pass

Chair’s remarks

Track 4
Christina Vandoros, Director, Macroeconomics & Health Policy - Emea, Janssen
Mar 1912:00
Conference pass

Chair’s remarks

Track 5
Omar Dabbous, VP, Health Economics And Outcomes Research, AveXis
Mar 1912:00
Conference pass

Chair’s remarks

Track 6
Giuseppe Rosano, Member Of The Cardiovascular Working Party, European Medicines Agency
Mar 1912:05
Conference pass

Federated & Harmonised Real World Evidence in the EU 2020+: A Convergence of Intent, Collaboration & Technology?

Track 1
Mar 1912:05
Conference pass

Innovation in treating rare diseases: HTA approach in Scotland

Track 3
Mark Macgregor, Co-Vice Chair, Scottish Medicines Consortium, Nhs Scotland
Mar 1912:05
Conference pass

Political factors when considering affordability

Track 4
Mar 1912:05
Conference pass

Risk sharing agreements for cell and gene therapies

Track 5
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Mar 1912:05
Conference pass

Experiences from managed entry agreements

Track 6
Bart Van Den Daele, Head of External Affairs – Director Market Access, Gilead Sciences
Mar 1912:45
Conference pass

Innovative payment and evidence development models for rare diseases

Track 3
Simon Shohet, Senior Director, Global Market Access And Pricing, Ipsen
Mar 1912:45
Conference pass

Solving the Affordability Challenge – what pharma companies can do beyond philanthropy

Track 4
John Alter, Vice President Pricing And Market Access, Pfizer
Mar 1912:45
Conference pass

Solving the Affordability Challenge – what pharma companies can do beyond philanthropy

Track 5
John Alter, Vice President Pricing And Market Access, Pfizer
Mar 1914:05
Conference pass

Chair’s remarks

Track 3
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Mar 1914:05
Conference pass

Chair’s remarks

Track 4
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1914:05
Conference pass

Chair’s remarks

Track 5
Adam Heathfield, Senior Director of Global Health And Value Innovation Centre, Pfizer Ltd
Mar 1914:05
Conference pass

Chair’s remarks

Track 6
Rudy Dupree, Senior Project Manager, Eunethta Wp4, EUnetHTA
Mar 1914:10
Conference pass

Latest Pricing Developments for Germany

Track 2
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer-Ingelheim
Mar 1914:10
Conference pass

The incentives’ review by the EU Commission and its implication on OMPs

Track 3
Ana Palma, Senior Director Global Hta And Patient Access Lead, Sobi
Mar 1914:10
Conference pass

Achieving Sustainability in Biosimilars

Track 4
Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Mar 1914:10
Conference pass

How to evaluate and value gene therapies

Track 5
Omar Dabbous, VP, Health Economics And Outcomes Research, AveXis
Mar 1914:10
Conference pass

Experiences from a payer point of view: insights from Denmark

Track 6
Sune Lindgaard, Chief Of Business Intelligence, Amgros, Denmark
Mar 1914:30
Conference pass

The long-term sustainability of Biosimilars

Track 4
Maarten Van Baelen, Market Access Director, Medicines
Mar 1914:30
Conference pass

Topic tbc

Track 6
Entela Xoxi, Former Aifa, Universita Cattolica Del Sacro Cuore
Mar 1914:50
Conference pass

Market access for Germany

Track 2
Jorg Tomeczkowski, Head Of Market Access, Janssen Cilag Germany
Mar 1914:50
Conference pass

Where do we go from here - bridging the gap from regulatory approval to market access using MoCA

Track 3
Anna Bucsics, Project Advisor, MoCA - Mechanism of Coordinated Access to Orphan M
Mar 1914:50
Conference pass

A look at legislation for Biosimilars in Germany

Track 4
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
Mar 1914:50
Conference pass

Looking at Value for Advanced Therapies in Quebec

Track 5
Luc Boileau, Chairman and Chief Executive Officer, Inesss
Mar 1914:50
Conference pass

The patient perspective in managed entry agreements

Track 6
Rob Burley Burley, Director of Campaigns, Care & Support, The Muscular Dystrophy U.K.
Mar 1915:40
Conference pass

Chair’s remarks

Track 6
Dawn Torrence Ireland, President And Founder, C.H.E.R.U.B.S.
Mar 1915:45
Conference pass

Patient acceptability of self-injectables

Track 2
Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems
Mar 1915:45
Conference pass

Working with stakeholders to improve access to rare disease treatments

Track 3
Natasa Zibelnik, Global Head of Market Access, E.U.S.A. Pharma
Mar 1915:45
Conference pass

Innovative Value based contracting for gene therapies

Track 4
Kevin Mayo, Global Head Of Market Access And New Products, PTC Therapeutics
Mar 1915:45
Conference pass

Developments in patient advocacy

Track 6
Steve Sandor, Vice President, Market Access And Trade, Paratek Pharmaceuticals , Inc.
Mar 1916:05
Conference pass

tbc

Track 3
Melissa Paige, Uva Cancer Center, Oncology Patient Access Principal Coordinator, Patient Advocate, U.V.A. Health System
Mar 1916:05
Conference pass

Latest developments on indication-based pricing

Track 4
Bertrand Tardivel, General Manager, Frehel GmbH
Mar 1916:05
Conference pass

Patient financial toxicity: challenges and options

Track 6
Robert Orzechowski, Chief Operating Officer, Lancaster Cancer Centre
Mar 1916:25
Conference pass

Using RWE and patient advocacy to ensure patient access in rare disease drug launch

Track 3
Peter Rutherford, Global Medical Lead Of Orphan Renal Diseases, Vifor Pharma Group
Mar 1916:25
Conference pass

Innovative contracting and payment models for cell and gene therapies

Track 4
Ramesh Arjunji, Senior Director Heor And Rwe, AveXis
Mar 1916:25
Conference pass

Developments in CAR-T and latest regulatory requirements

Track 5
Detlev Parow, Head Pharmaceutical Department, D.A.K.
Mar 1916:25
Conference pass

The value provided to pharma through patient advocacy – hard lessons learnt from industry

Track 6
Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement
last published: 15/Jul/19 11:35 GMT

Contact us

To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052

edmond.rama@terrapinn.com

To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com